news

Oxford Global’s free webinars: “drug discovery – what will the future hold?” registration open

Posted: 4 March 2016 | Oxford Global | No comments yet

This upcoming webinars hosted by Oxford Global will provide an insight on Drug Discovery & Antibody Research…

Webinar : March 15th | 2:30 pm GMT “Nanobodies as a Versatile and Clinically Validated Approach” hosted by Tony De Fougerolles, Chief Scientific Officer at Ablynx

This exciting webinar will discuss the exciting new antibody technology being developed by Ablynx, and aims to give attendees insight into the future of antibody discovery and development. Single domain antibodies represent a potential avenue for overcoming some of the limitations encountered by conventional antibody technology. As a leader in the field with over 40 active drug programmes, Ablynx has world-leading insight and experience in the use of immunoglobulin single variable domains, which we term Nanobodies®. Using both preclinical and clinical stage compounds as case studies, it will be shown how the use of Nanobodies can successfully address a range of concrete and distinct limitations of conventional antibody technology.

Register for free here

Webinar: March 22nd | 2:30 pm GMT “Open Innovation and partnerships for an improved Lead Generation” hosted by Patrick Jimonet, External Opportunities in Drug Discovery, Sanofi

This webinar will discuss a range of drug discovery strategies:

 

Reserve your FREE place

 


Are you advancing promising antibody leads, only to encounter issues with stability, PK or manufacturability later in development?

30 July 2025 | 10:00 AM BST | FREE Webinar

Join us for an expert-led webinar exploring how early-stage developability assessment can help reduce downstream risk and improve candidate selection.

What You’ll Learn:

  • How to identify key developability risks early including aggregation, PK, and manufacturability
  • How to implement high-throughput in vitro assays requiring <1 mg of antibody per test
  • How to combine in silico modeling with wet-lab analytics to guide early optimisation

Don’t miss your chance to learn from Dr Lei Guo.

Register Now – It’s Free!

 

  • Diversity of modalities is required to drug challenging targets of pharma portfolios
  • Hit Finding strategy: critical role of innovation and partnerships
  • New business models to access novel chemical matter and technologies
  • Macrocycles and cyclic peptides to drug proteins that failed with small molecules and/or that are not accessible to antibodies
  • Open innovation, e.g. crowdsourcing, a new mindset to improve drug discovery efficiency

Register for free here

Benefits to Attending:

  • Advance your knowledge of antibody technologies and the common challenges faced by researchers
  • Hear about the latest strategies for open innovation in drug discovery, across small and large molecules
  • Learn from a leading expert about his experience in antibody discovery
  • Hear about an innovative approach to antibody technology and also open innovation, and have the opportunity to put your questions to our industry experts

You can also discover even more and discuss the latest topics in drug discovery and medicinal chemistry on our social media:

Twitter: https://twitter.com/drugdiscovery1
LinkedIn: Drug Discovery & Development Network Group

Related topics

Related organisations

Leave a Reply

Your email address will not be published. Required fields are marked *